{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:16:02Z","timestamp":1788142562596,"version":"build-2803163510"},"reference-count":22,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Vogenx, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Postbariatric hypoglycemia (PBH) is a complication of bariatric surgery characterized by severe postprandial hypoglycemia for which there is no approved therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate efficacy and safety of mizagliflozin, a sodium glucose cotransporter 1 inhibitor, for treatment of PBH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a phase 2, open-label, randomized, single-dose, crossover study. Nine participants with PBH were randomized to receive a baseline mixed meal tolerance test (MMTT), and single doses of mizagliflozin before each of 2 additional MMTTs. Doses included a 2.5-mg liquid formulation, and 2.5-, 5-, and 10-mg capsules. The primary outcome was change from baseline in glucose nadir, and the main secondary outcomes were change from baseline peak glucose and peak insulin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to baseline, all individual doses of mizagliflozin raised the glucose nadir: 6.2\u2005mg\/dL (2.5-mg capsule), 17.5\u2005md\/dL (2.5-mg liquid), 4.0\u2005mg\/dL (5-mg capsule) and 31.5\u2005mg\/dL (10-mg capsule). In a post hoc analysis of participants that exhibited hypoglycemia (&amp;lt;70\u2005mg\/dL) during the baseline MMTT, mizagliflozin (all capsule doses combined) raised the glucose nadir by 38% (P = .03). Treatment with mizagliflozin also lowered both peak glucose by 21% (P = .03) and peak insulin by 53% (P = .016). Glucose-dependent insulinotropic peptide area under the curve0-3h was reduced by 45% from baseline (P = .048).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Mizagliflozin resulted in improved glucose nadir, reduction in both postprandial peak glucose and peak insulin, and reduction in postprandial glucose-dependent insulinotropic polypeptide. The results from this proof-of-concept study suggest mizagliflozin represents a promising novel oral treatment for PBH that warrants further clinical development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvag181","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:40:00Z","timestamp":1787658000000},"source":"Crossref","is-referenced-by-count":0,"title":["A single dose trial of mizagliflozin for the treatment of postbariatric hypoglycemia"],"prefix":"10.1210","volume":"10","author":[{"given":"Helen M","family":"Lawler","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Colorado School of Medicine , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4829-8649","authenticated-orcid":false,"given":"Tracey L","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism, and Diabetes, Division of Endocrinology, Gerontology, and Metabolism, Department of Medicine, Stanford University School of Medicine , Stanford, CA 94305 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soroush","family":"Shakeri","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado School of Medicine , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan F","family":"Stortz","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado School of Medicine , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aanchal","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado School of Medicine , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7095-245X","authenticated-orcid":false,"given":"Vatsala","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado School of Medicine , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8313-3084","authenticated-orcid":false,"given":"Nicole","family":"Turk","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism, and Diabetes, Division of Endocrinology, Gerontology, and Metabolism, Department of Medicine, Stanford University School of Medicine , Stanford, CA 94305 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Walker","sequence":"additional","affiliation":[{"name":"Vogenx, Inc. , Raleigh, NC 27609, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wilkison","sequence":"additional","affiliation":[{"name":"Vogenx, Inc. , Raleigh, NC 27609, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9201-5602","authenticated-orcid":false,"given":"Bentley","family":"Cheatham","sequence":"additional","affiliation":[{"name":"Vogenx, Inc. , Raleigh, NC 27609, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"6","key":"2026083021363184700_bvag181-B1","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/oby.21520","article-title":"How common is hypoglycemia after gastric bypass?","volume":"24","author":"Goldfine","year":"2016","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"2026083021363184700_bvag181-B2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0889-8529(18)30396-7","article-title":"Reactive hypoglycemia","volume":"18","author":"Hofeldt","year":"1989","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"11","key":"2026083021363184700_bvag181-B3","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1007\/s00125-010-1884-8","article-title":"Hypoglycaemia following gastric bypass surgery\u2013diabetes remission in the extreme?","volume":"53","author":"Patti","year":"2010","journal-title":"Diabetologia"},{"issue":"6","key":"2026083021363184700_bvag181-B4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.soard.2026.03.013","article-title":"Prevalence of post-bariatric hypoglycemia in the United States","volume":"22","author":"Craig","year":"2026","journal-title":"Surg Obes Relat Dis"},{"issue":"8","key":"2026083021363184700_bvag181-B5","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1210\/jc.2018-00528","article-title":"Hypoglycemia after gastric bypass surgery: current concepts and controversies","volume":"103","author":"Salehi","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026083021363184700_bvag181-B6","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s11695-007-9102-6","article-title":"Hyperinsulinemic hypoglycemia developing late after gastric bypass","volume":"17","author":"Bantle","year":"2007","journal-title":"Obes Surg"},{"issue":"4","key":"2026083021363184700_bvag181-B7","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1210\/jc.2009-1628","article-title":"Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery","volume":"95","author":"McLaughlin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026083021363184700_bvag181-B8","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1007\/s11695-014-1319-6","article-title":"Effect of carbohydrate restriction in patients with hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass","volume":"24","author":"Botros","year":"2014","journal-title":"Obes Surg"},{"issue":"4","key":"2026083021363184700_bvag181-B9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.soard.2008.05.005","article-title":"Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet","volume":"4","author":"Kellogg","year":"2008","journal-title":"Surg Obes Relat Dis"},{"issue":"2","key":"2026083021363184700_bvag181-B10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3122\/jabfm.2024.240335R1","article-title":"Diagnosis and management of post-bariatric hypoglycemia","volume":"38","author":"Lawler","year":"2025","journal-title":"J Am Board Fam Med"},{"issue":"5","key":"2026083021363184700_bvag181-B11","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.soard.2017.01.025","article-title":"Medical nutrition therapy for post-bariatric hypoglycemia: practical insights","volume":"13","author":"Suhl","year":"2017","journal-title":"Surg Obes Relat Dis"},{"key":"2026083021363184700_bvag181-B12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejphar.2017.04.010","article-title":"Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation","volume":"806","author":"Inoue","year":"2017","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"2026083021363184700_bvag181-B13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/00498254.2018.1449269","article-title":"Absorption, disposition, metabolism and excretion of [(14)C]mizagliflozin, a novel selective SGLT1 inhibitor, in rats","volume":"49","author":"Ohno","year":"2019","journal-title":"Xenobiotica"},{"issue":"1","key":"2026083021363184700_bvag181-B14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/db11-1029","article-title":"Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion","volume":"61","author":"Gorboulev","year":"2012","journal-title":"Diabetes"},{"issue":"10","key":"2026083021363184700_bvag181-B15","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/oby.20829","article-title":"Upregulation of intestinal glucose transporters after Roux-en-Y gastric bypass to prevent carbohydrate malabsorption","volume":"22","author":"Nguyen","year":"2014","journal-title":"Obesity (Silver Spring)"},{"issue":"8","key":"2026083021363184700_bvag181-B16","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2927","article-title":"Gut microbiome response to short-term dietary interventions in reactive hypoglycemia subjects","volume":"33","author":"Quercia","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"issue":"20","key":"2026083021363184700_bvag181-B17","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"2026083021363184700_bvag181-B18","doi-asserted-by":"crossref","first-page":"e1235","DOI":"10.1210\/clinem\/dgz258","article-title":"Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption","volume":"105","author":"Powell","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026083021363184700_bvag181-B19","doi-asserted-by":"crossref","first-page":"G946","DOI":"10.1152\/ajpgi.00286.2014","article-title":"Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release","volume":"308","author":"Dobbins","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"8","key":"2026083021363184700_bvag181-B20","doi-asserted-by":"crossref","first-page":"e3235","DOI":"10.1210\/clinem\/dgab103","article-title":"PREVENT: a randomized, placebo-controlled crossover trial of avexitide for treatment of postbariatric hypoglycemia","volume":"106","author":"Craig","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026083021363184700_bvag181-B21","doi-asserted-by":"crossref","DOI":"10.18549\/PharmPract.2016.04.832","article-title":"Effects of the addition of acarbose to insulin and non-insulin regimens in veterans with type 2 diabetes mellitus","volume":"14","author":"Wettergreen","year":"2016","journal-title":"Pharm Pract (Granada)"},{"issue":"3","key":"2026083021363184700_bvag181-B22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/dom.14920","article-title":"Medical and surgical treatment of postbariatric hypoglycaemia: retrospective data from daily practice","volume":"25","author":"de Heide","year":"2023","journal-title":"Diabetes Obes Metab"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvag181\/70792233\/bvag181.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/9\/bvag181\/70792233\/bvag181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/9\/bvag181\/70792233\/bvag181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T01:36:41Z","timestamp":1788140201000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvag181\/8770885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvag181","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,1]]},"article-number":"bvag181"}}